ORGO Organogenesis Holdings (A)

Organogenesis Holdings Inc. to Participate in the ICR Conference 2021

Organogenesis Holdings Inc. to Participate in the ICR Conference 2021

CANTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will attend the ICR Conference 2021, which is being held virtually from January 11th-14th. Management will participate in a fireside chat on Thursday, January 14th at 1:45 p.m. Eastern Time.

A live audio webcast of the conference presentation will be accessible by visiting the “Upcoming Events” section on the “Investor Relations” page of Organogenesis’s website An archive of the webcast will be available for replay following the conference for approximately 30 days.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit .



Investor Inquiries:
Westwicke Partners
Mike Piccinino, CFA
 
443-213-0500

Press and Media Inquiries:
Organogenesis
Marcus Girolamo
  
817-688-4767
EN
05/01/2021

Underlying

ORGOOrganogenesis Holdings (A)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Organogenesis Holdings (A)

 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. to Participate in Upcoming Investor Confer...

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September CANTON, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the following upcoming investor conferences: The Cantor Fitzgerald Global Healthcare Conference at the New York Marriott Marquis in New York, NY Management will partic...

August 27, 2025 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Resu...

Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compared...

August 7, 2025 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 20...

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025 CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that second quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, August 7th. Management will host a conference call at 5:00 p.m. Easter...

July 22, 2025 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment ...

Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation CANTON, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, applauds the Centers for Medicare & Medicaid Services’ (CMS) proposed new payment approach for skin substitutes/cellular and tissue-based ...

July 15, 2025 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Resul...

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Summary: Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to n...

May 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch